BRCA1 is a nuclear phosphoprotein that has been classi®ed as a tumor suppressor based on the fact that women carrying a mutated copy of the BRCA1 gene are at increased risk of developing breast and ovarian cancer. The association of BRCA1 with RAD51 has led to the hypothesis that BRCA1 is involved in DNA repair. We describe here the generation and analysis of murine embryonic stem (ES) cell lines in which both copies of the murine homologue of the human BRCA1 gene have been disrupted by gene targeting. We show that exogenous DNA introduced into these BRCA1 de®cient cells by electroporation is randomly integrated into the genome at a signi®cantly higher rate than in wild type ES cells. In contrast, integration of exogenous DNA by homologous recombination occurs in BRCA1 de®cient cells at a signi®cantly lower rate than in wild type controls. When BRCA1 expression is re-established at 5 ± 10% of normal levels by introduction of a Brca1 transgene into BRCA1 de®cient ES cells, the frequency of random integration is reduced to wild type levels, although the frequency of homologous recombination is not signi®cantly improved. These results suggest that BRCA1 plays a role in determining the response of cells to double stranded DNA breaks.
Introduction
BRCA1 is a nuclear protein that has been classi®ed as a tumor suppressor based on the fact that inheritance of one defective copy of the BRCA1 gene confers an estimated 80 ± 90% overall lifetime risk for breast or ovarian cancer (Easton et al., 1993; Miki et al., 1994) . A number of approaches have been taken in the attempt to understand at a molecular and cellular level how loss of functional BRCA1 leads to cellular transformation and tumorigenesis. These include analysis of the primary structure of the BRCA1 protein, elucidation of the interaction of BRCA1 with other proteins, examination of the temporal and spatial pattern of BRCA1 expression, and determination of the eects of mutations in the murine homologue of the BRCA1 gene in both cell lines and whole animals. Taken together, the results of these experiments support a role for BRCA1 in several cellular processes, including transcription (Chapman and Verma, 1996; Monteiro et al., 1996) , cell cycle transition (Larson et al., 1997; Xu et al., 1999) , and DNA repair (Scully et al., 1997a,b; Gowen et al., 1998; Shen et al., 1998; Zhong et al., 1999) . Of these processes, the evidence gathered to date appears to provide the strongest support for a role of BRCA1 in DNA repair.
Analysis of the primary structure of BRCA1 has revealed a number of potential functional motifs, including a RING ®nger domain in the N-terminus and two putative nuclear localization sequences (Wu et al., 1996; Thakur et al., 1997; Chen et al., 1996a) . In addition, two BRCT domains, characteristic of proteins involved in DNA repair, have been identi®ed in the C-terminus of BRCA1 (Callebaut and Mornon, 1997) .
While it was originally thought that BRCA1 was expressed in only a subset of tissues (Miki et al., 1994) , studies using the murine homologue Brca1 (Bennet et al., 1995; Sharan et al., 1995) , showed that expression could be detected early in embryo development and that Brca1 continued to be expressed in a broad spectrum of tissues throughout development and into adulthood (Marquis et al., 1995; Lane et al., 1995) . Additional studies showed that BRCA1 expression could be detected in virtually all dividing cells in a cell cycle speci®c manner, with maximal expression of BRCA1 occurring in S phase (Chen et al., 1996b; Runer and Verma, 1997) . The level of phosphorylation of BRCA1 also changes throughout the cell cycle, peaking in late S phase. It was, however, the seminal experiments by Scully et al. (1997a) examining the localization of BRCA1 within the nucleus, that provided evidence for a role for BRCA1 in DNA repair. These experiments demonstrated that exposure of cells to DNA damaging agents results in hyperphosphorylation of BRCA1 and relocalization of BRCA1 with RAD51 to PCNA-containing foci. RAD51 has been implicated in DNA repair, as demonstrated by the high sensitivity of S. cerevisiae rad51 mutants to DNA-damaging agents (Game, 1983; Shinohara et al., 1992) . A similar approach has recently shown that BRCA1 can also colocalize in nuclear foci with RAD50 after exposure to ionizing radiation (Zhong et al., 1999) .
BRCA1 function has also been examined using a number of mouse lines in which the Brca1 gene has been inactivated by gene targeting (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) . Unlike humans, mice carrying a mutant Brca1 allele do not display an increased risk for tumor formation (Cressman et al., 1999b) . More recently, however, mice heterozygous for null mutations at both the Brca1 locus and the p53 locus have been shown to develop mammary tumors after exposure to ionizing radiation (Cressman et al., 1999b) .
Mice homozygous for mutant Brca1 die early in development with BRCA1 de®cient embryos of all lines displaying severe growth retardation (Snouwaert et al., 1998) . One possible explanation for this is that growth arrest occurs in response to the accumulation of deleterious mutations caused by faulty DNA repair. Evidence for this is provided by the ®nding that the growth of BRCA1 de®cient blastocysts is reduced relative to wild type controls after exposure to ionizing radiation in vitro (Shen et al., 1998) . Another line of support comes from the ®nding by several groups that the development of BRCA1 de®cient embryos is extended if the embryos are also p53 de®cient (Hakem et al., 1997; Ludwig et al., 1997. A small number of Brca1
p53 7/7 mice have survived to adulthood, and examination of the male BRCA1 de®cient animals suggests that BRCA1 plays an important role in spermatogenesis (Cressman et al., 1999a) . The testes of these animals show a reduced number of spermatocytes and an absence of round spermatids. This is consistent with the previously reported ®nding that Brca1 is expressed at high levels in the adult testes (Miki et al., 1994; Lane et al., 1995; Zabludo et al., 1996) . In addition, examination of the seminiferous tubules by in situ analysis has shown that Brca1 expression is highest in spermatocytes, and in particular in those in the late pachytene and diplotene stages of the ®rst meiotic prophase (Blackshear et al., 1998) . Immunohistological studies indicate that BRCA1 is associated with unsynapsed axial elements as well as axes in the process of synapsing in the prophase spermatocyte (Scully et al., 1997b) . BRCA1 has also been detected on unsynapsed centromeric heterochromatin, on remaining univalent chromosomes, and at pairing forks. In most instances, BRCA1 has been reported to colocalize with RAD51 in the prophase spermatocyte chromosomes. Thus, both the localization of BRCA1 in spermatocytes and the phenotype of the BRCA1 de®cient male mice are consistent with an essential role for BRCA1 in meiosis.
Use of Brca1 de®cient mice as a source of primary cell lines has been limited by the fact that these animals die early in embryogenesis. However, a mouse embryonic stem (ES) cell line homozygous for a mutant Brca1 allele has been generated by two rounds of gene targeting. Exposure BRCA1 de®cient ES cells to DNA damaging agents has revealed that, relative to ES cells carrying a functional Brca1 gene, BRCA1 de®cient cells display increased sensitivity to DNA damaging agents such as ionizing radiation . These cells have also been shown to be incapable of carrying out transcriptional-coupled repair (TCR) after exposure to ionizing radiation and H 2 O 2 . This repair system preferentially directs repair of damaged DNA to the transcribed strand of active genes and is essential for the removal of lesions for which the global repair process is too slow.
The demonstration of defective TCR in the BRCA1 de®cient ES cells provided the ®rst direct evidence for a DNA repair function for BRCA1. However, it has not been determined whether the hypersensitivity of these cells to DNA damaging agents, and in particular to ionizing radiation, is due solely to loss of TCR function, or whether de®cits in other types of DNA repair processes might be involved. Although ionizing radiation does lead to oxidative damage of DNA, studies have suggested that the cellular lethality observed after exposure to this DNA damaging agent results from unrepaired or incorrectly repaired doublestranded breaks (DSBs) (Ward, 1995) . Homologous recombination is believed to contribute to the maintenance of genomic integrity through the precise repair of a chromosomal DSB using the sister chromatid as the repair template (Johnson et al., 1999) . However, homologous repair of chromosomal DSBs using other homologous templates, such as repeated sequences, is potentially deleterious, since it can result in loss of heterozygosity or chromosomal translocations (Moynahan and Jasin, 1997; Richardson et al., 1998) . Rad51 has been shown in yeast to promote homology-dependent DNA repair of double strand breaks. A role for BRCA1 in this repair pathway is suggested by its association with this protein, both in somatic cells after exposure to DNA damaging agents, and on the synaptonemal complex during meiosis. Mammalian cells can also repair double stranded breaks by non-homologous end joining (NHEJ) (Liang et al., 1998) . Rad50, Mre11 and p95/nibrin form a complex that functions in homologous recombination and in NHEJ, meiotic recombination, the DNA damage response, and telomere maintenance (Haber, 1998) . The association of BRCA1 with these foci suggests that it may also be involved in repair of DSB by other pathways such as NHEJ.
To determine the role of BRCA1 in homologous recombination and NHEJ, we have examined the frequencies of homologous and non-homologous integration of plasmid DNA into the genome of BRCA1 de®cient ES cells. We report here that both of these processes are altered in BRCA1 de®cient cells, and that expression of a Brca1 transgene in these cells reverses the alteration in non-homologous recombination although homologous recombination frequencies are not improved.
Results

Generation of the BRCA1 de®cient cell line
A schematic of the various manipulations employed in generating the BRCA1 de®cient cell lines used in these studies is shown in Figure 1 . The generation of murine ES cell lines in which one Brca1 allele is disrupted by homologous recombination has been described previously (Gowen et al., 1996) . These lines were derived from the E14TG2a ES cell line, which is 6-TG resistant due to a spontaneous deletion that resulted in loss of the 5' portion of the hprt gene (Hooper et al., 1987) . Upon integration into the E14TG2a genome by homologous recombination, the targeting vector used to disrupt the Brca1 gene replaced the 3' portion of intron 10 and the 5' portion of exon 1 with the neomycin gene. This mutation has previously been designated Brca1 D223-763 (Snouwaert et al., 1998) . However, as all of the cell lines discussed here carry this mutation, for simplicity, we refer to mice and cells carrying this mutation as Brca1 +/7 or Brca1 7/7 in this report. To generate ES cell lines incapable of expressing wild type Brca1, a second targeting vector was prepared. This vector diers primarily in that, upon undergoing homologous recombination with the endogenous sequences, it replaces a portion of the Brca1 gene with an hprt minigene rather than the gene encoding neomycin phosphotransferase (neo).
The targeting vector containing the hprt minigene was electroporated into Brca1
ES cells, and colonies obtained after selection in HAT medium were expanded and analysed by Southern blot analysis. Targeting events were detected using a probe that binds to sequences just downstream of those used for construction of the targeting plasmids. Targeting of the neo plasmid results in the generation of a 5.9 kb EcoRV DNA fragment recognized by this probe. An increase in the size of the EcoRV fragment that hybridizes with this probe is seen upon targeted integration of the hprt containing targeting plasmid (data not shown). Six independent electroporations yielded 267 HAT-resistant colonies. These colonies were expanded and DNA prepared for Southern blot analysis. In 12 of these clones, the size of the DNA fragments observed with the Brca1 speci®c probe indicated that the plasmid had undergone homologous recombination with the previously targeted Brca1 allele. Southern analysis of DNA prepared from one of the clones revealed the presence of fragments arising from both neo and hprt targeted Brca1 alleles. A third band, corresponding to the wild type locus, could also be seen on Southern analysis of this DNA sample, indicating that the culture was contaminated with Brca1 +/7 ES cells. Subcloning of these ES cells yielded a number of isolates that Southern analysis indicated contained only the DNA fragments corresponding to the two targeted Brca1 alleles.
We examined the eect of BRCA1 de®ciency on homologous recombination using a vector designed to correct the endogenous mutant hprt locus of the E14TG2a cell line. To accomplish this, it was necessary to isolate BRCA1 de®cient ES cells that had lost the function of the hprt minigene. We therefore screened for Brca1 7/7 cells in which the hprt minigene had been lost through a spontaneous deletion mutation by subjecting the double targeted ES cell line to selection against HPRT function. The Brca1 7/7 cell line was grown in medium containing 6-TG, and colonies appearing after 10 ± 14 days of growth in the selective medium were expanded. DNA was prepared from the resulting 6-TG resistant cell lines and analysed by Southern blot. A probe speci®c for the hprt minigene failed to hybridize to DNA from these lines, while a Brca1 speci®c probe that recognizes Brca1 sequences just downstream of the targeted region detected only the neo targeted locus. This indicated that resistance to 6-TG was due to loss of the hprt minigene and at least some surrounding Brca1 sequences.
RNA was prepared from one such clone, and Northern blot analysis using a cDNA probe corresponding to exons 2 ± 10 of the mouse Brca1 mRNA failed to reveal the presence of wild type Brca1 mRNA (Figure 2) . However, the probe did reveal the presence of a band apparently corresponding to a small novel transcript derived from the neo targeted loci. A band of identical electrophoretic mobility is also seen in RNA derived from the Brca1 +/7 and the Brca1 7/7 parental lines (data not shown). RNA prepared from the Brca1 7/7 hprt 7 line was subjected to RTPCR using primers corresponding to sequences in exon 8 and 21 of the BRCA1 gene. The sequence of the resulting cDNA fragment indicated that, in the novel transcript, exon 10 is spliced directly to exon 12. This mRNA message remains in frame despite the loss of exon 11. 7/7 ES cell lines. A cell line in which a neomycin gene replaced a portion of intron 10 and the 5' portion of exon 11 was transfected with a Brca1 targeting vector designed to replace the identical region of the remaining wild type Brcal gene with an hprt minigene. This line was identi®ed by growth in HAT containing media and Southern blot analysis to identify the cells in which the plasmid had undergone homologous recombination with the wild type locus. Once identi®ed the Brca1 7/7 cell line was expanded and then subjected to growth in 6-TG containing media. Surviving colonies were expanded and analysed and those in which resistance to 6-TG was the result of a deletion of the hprt minigene identi®ed
Comparison of the frequency of non-homologous and homologous recombination at the hprt locus in wild type and BRCA1 de®cient ES cells
To examine the eect of BRCA1 de®ciency on homologous and non-homologous recombination, we used an assay in which either type of event can be scored by screening cells for the presence of a functional hprt gene. To assay homologous recombination events we used a system in which the deletion mutation in the hprt locus of the E14TG2a ES cell line is corrected by homologous recombination with a targeting plasmid, pMP8 (Figure 3) (Reid et al., 1991) . To assay for random integration events cells were transfected with a plasmid, hprt50, carrying an hprt minigene (Figure 4) . In both types of assay, cells were transfected with plasmid DNA and then subjected to selection on HAT medium. For each electroporation, cells were also plated in regular medium to determine the percentage of cells surviving electroporation. The results of the electroporation were scored as the number of cells surviving in selective medium over the number surviving in non-selective medium. For each experiment, the fraction of HAT resistant colonies for each cell line was expressed as a percentage of the number of resistant colonies obtained with the E14TG2a ES cells, which was assigned a value of 100%. As can be seen in Figure 3 , the number of targeting events obtained on transfection of the Brca1 +/7 cell lines with pMP8 is not signi®cantly dierent from that obtained with the parental E14TG2a line. In contrast, both of the Brca1 7/7 ES cell lines show a signi®cant decrease in the frequency of correction of the hprt locus.
We next compared the frequency with which the Brca1 +/7 and Brca1 7/7 lines were transformed by the plasmid carrying the hprt minigene. While the transformation frequencies of the E14TG2a and
Brca1
+/7 lines were similar, a dramatic increase in frequency was observed with each of the Brca1
lines.
Previous studies have indicated that frequencies of homologous recombination can be in¯uenced by the time interval between electroporation and exposure to selection (Templeton et al., 1997) . To examine the role of this factor in our assay systems, we carried out three experiments with E14TG2a and Brca1 7/7 cells in which the recovery time was extended from 24 ± 48 h. This increase in recovery time did not result in a signi®cant change in the relative frequencies of homologous or non-homologous recombination in the three lines (data not shown).
Homologous recombination at the Nr1 locus in BRCA1 de®cient cells
To determine whether the changes we observed in the frequency of homologous and non-homologous inte- Tg + line. The wild type message seen in the parental line is no longer expressed in the Brca1 7/7 line. However this line expresses a smaller novel Brca1 transcript. Upon transfection with the Brca1 transgene a BRCA1 message slightly smaller than normal transcript is seen. The reduced size is expected because of the use of a 3'UT of the growth hormone gene in this construct , Brca1 7/7 and Brca1
7/7
Tg + lines. The frequency of homologous recombination events was normalized to 100% and is indicated by the dotted line. The number of experiments carried out with each of the lines is indicated alongside the bar. The error bar represents the standard error of the mean. The values were subjected to ANOVA statistical analysis gration in BRCA1 de®cient cell lines were speci®c to the hprt locus, we examined targeting frequency at a second locus, the Nr1 locus. Brca1 +/+ and Brca 7/7 cells were electroporated with a vector designed to insert an hprt minigene into the Nr1 locus. A sample of the electroporated cells were plated at low density to determine the number of cells surviving electroporation, and the remainder were selected in HAT medium. Colonies were expanded and analysed by Southern blot. As can be seen in Table 1 , the frequency of random integration was about ten times higher in the Brca1 7/7 line. The apparent targeting frequency was decreased in the Brca1 7/7 line, but this change was less apparent when the frequency of homologous recombination was calculated based on starting cell numbers. Because the number of colonies analysed was small, it is dicult to make a conclusive statement on the frequency of homologous recombination in this experiment. Nevertheless, similar to the observations made at the hprt locus, the BRCA1 de®cient cells showed higher levels of non-homologous vs homologous recombination.
Correction of Brca1
7/7 ES cell lines with a Brca1 transgene As described above, of the 12 cell lines that were targeted with the Brca1 targeting plasmid containing the hprt minigene, only a single line was identi®ed in which the targeting event had occurred in the nontargeted, wild type Brca1 allele. Although we cannot rule out the possibility that this is due to preferential targeting of the already targeted allele, results suggest that homozygous loss of BRCA1 function confers some type of disadvantage on ES cells. It also raises the possibility that the single Brca1 7/7 line isolated may carry one or more genetic alterations that allow it to survive in the absence of functional BRCA1. It is, therefore, possible that the changes in the frequency of homologous and non-homologous recombination in this line result from mutations other than those in the Brca1 gene.
To determine whether this is the case, we constructed a plasmid, pBBrpAX, designed to correct the BRCA1 de®ciency in the Brca1
line. This plasmid carries a murine Brca1 cDNA transgene driven by a promoter derived from the endogenous murine Brca1 gene. The plasmid was originally designed to undergo homologous recombination with the Brca1 locus and thereby restore function to the hprt targeted Brca1 allele. Integration of pBBrpAX into this allele would not only restore function, but also displace the hprt minigene, allowing targeting events to be selected for by growth in medium containing 6-TG. Numerous experiments using this approach failed to yield a cell line in which the plasmid had integrated by homologous recombination. One possible explanation for the diculty in obtaining such cell lines is that, as described in the previous section, the homologous recombination frequency in Brca1
ES cells is reduced relative to that in the lines from which it was derived.
Because pBBrpAX contains the full coding sequence of Brca1 as well as the bovine growth hormone polyadenylation signal, we attempted to obtain expression from the plasmid by isolating ES cells in which it had integrated randomly. To accomplish this, we cotransfected Brca1 7/7 cells with the pBBrpAX and a plasmid carrying a gene for puromycin resistance. Puromycin resistant colonies were isolated, expanded, and analysed by Southern blotting for the presence of the transgene. RNA was prepared from cells carrying the transgene, and the level of expression of the transgene was determined by Northern analysis. Expression of the transgene could be detected in only a small percentage of the isolates, and the highest expression levels obtained were in the range of 5 ± 10% of that seen in E14TG2a cells (Figure 2, lane 3) .
Homologous and non-homologous recombination in the Brca1
7/7
Tg +
ES cell line
Homologous and non-homologous recombination were assayed in the Brca1
7/7
Tg + ES cell line as described above for the Brca1 +/7 and Brca1 7/7 ES cell lines. As seen in Figure 4 , the frequency of random integration in the corrected line was reduced to that of the Brca1 +/+ E14TG2a line. In contrast, the decreased frequency of homologous recombination seen in the Brca1 7/7 cell line was not signi®cantly improved by expression of the Brca1 transgene (Figure 3 ).
Discussion
We have used a BRCA1 de®cient ES cell line to aid in determining whether BRCA1 might play a role in homologous or non-homologous recombination. This Brca1 7/7 line was generated by subjecting an ES cell line in which one Brca1 allele had been inactivated by gene targeting to a second round of mutagenesis. Inactivation of the second Brca1 allele in this line was carried out using a targeting plasmid that diered from the ®rst only in the selectable marker gene that it carried. Thirteen ES cell lines were identi®ed in which the targeting plasmid had integrated by homologous recombination. However, in 12 of these lines, the plasmid had integrated into the previously targeted allele. Although it is possible that this is due to preferential targeting of the already targeted allele, diculty in obtaining Brca1 7/7 cell lines has also been reported by others and is consistent with the observation that loss of Brca1 expression is deleterious to the survival of most cell types (Hakem et al., 1996) . Another possibility is that the one Brca1 7/7 cell line that was identi®ed had undergone other, unidenti®ed genetic alterations that allowed it to survive in the absence of functional BRCA1. For instance, it has been shown that acquisition of mutations that give cells a growth advantage, such as loss of p53 or p21, extend the survival of Brca1 7/7 embryos and ®broblasts (Ludwig et al., 1997; Hakem et al., 1997; Cressman et al., 1999a; Xu et al., 1999) . Although Western analysis indicated that our Brca1 7/7 ES cells are still capable of expressing normal levels of both p53 and p21 (data not shown), we have not sequenced the genes to rule out the possibility that they have undergone point mutations that aect their function.
Brca1 expression was re-established in the double targeted ES cell line by generating a Brca1 transgene that placed the Brca1 gene under the control of a 4.5 kb fragment derived from sequences directly upstream of the Brca1 start site. This fragment encompasses the entire intergenic region between the start sites of the Brca1 and Nbr1 genes, as well as the ®rst exons of the Nbr1 gene (Chambers and Solomon, 1996) . However, the ES lines carrying the transgene were found to express Brca1 at 10% or less of that observed in the parental cell lines carrying the intact endogenous locus. This low level of expression may arise from the fact that the transgene lacks intronic or downstream sequences that are necessary for wild type expression levels, or it may be that cells that express high levels of the transgene at inappropriate times during the cell cycle do not survive. Diculty in obtaining stable expression from BRCA1 transgenes has been noted by others, although transient expression of BRCA1 has been shown recently to correct the loss of formation of foci in BRCA1 de®cient tumor cell lines (Zhong et al., 1999) .
We found that BRCA1 de®cient ES cells displayed a decreased frequency of homologous recombination and an increased frequency of non-homologous recombination relative to the parental, Brca1-expressing lines from which they were generated. These dierences were seen in nine separate experiments and in two, separately isolated, Brca1 7/7 subclones. These results are consistent with observations by Moynahan et al. (1999) using these cells.
We found that even the low level of Brca1 expression obtained with our transgene construct was sucient to reduce the frequency of non-homologous recombination to normal levels, supporting the interpretation that the increased frequency of nonhomologous recombination observed in our Brca1 7/7 cells resulted directly from inactivation of the Brca1 locus. On the other hand, Brca1 expression from the transgene did not signi®cantly improve the frequency of homologous recombination. We do not know if this is due to poor or temporally inappropriate expression of the transgene or to some other factor.
A role for BRCA1 in homologous recombination would be consistent with the reported association of BRCA1 with RAD51 (Scully et al., 1997a) , BRCA1 with RAD50 (Scully et al., 1997b) and with the observed failure of meiosis in Brca1
spermatocytes (Cressman et al., 1999a) . It has also been reported recently that BRCA1 localizes independently with both RAD51 and RAD50 containing nuclear foci after exposure of cells to ionizing irradiation, but cells have either RAD51 containing foci or RAD50 containing foci, but not both (Zhong et al., 1999) . Non-homologous integration of DNA is believed to occur largely by non-homologous end joining (NHEJ), which has been reported to involve Rad50, and it is possible that NHEJ may be dependant on the association of BRCA1 with RAD50.
The results reported here support the emerging view that BRCA1 plays an important role in a number of DNA repair pathways including TCR, homologous recombination and, perhaps, NHEJ. Disruption of these repair pathways would explain how loss of BRCA1 function leads to embryonic lethality in the mouse embryo and to loss of growth potential in virtually all non-transformed cells. Accumulation of mutations in cells in the developing Brca1 7/7 embryo could lead to cell death or senescence and, eventually, to death of the embryo. Early embryonic lethality has also been noted in mice homozygous for null mutations in the genes encoding Rad50 and Rad51, respectively (Lim and Hasty, 1996; Luo et al., 1999; Tsuzuki et al., 1999) . Future experiments that further elucidate the molecular mechanisms by which BRCA1 contributes to the repair or damaged DNA will be important in determining which of these pathways contribute both to malignant transformation of epithelial tissue and growth early in embryogenesis.
Materials and methods
Generation of the Brca1 targeting vector
Construction of the Brca1 targeting vector containing the neomycin phosphotransferase resistance marker (neo) has been described previously. Construction of the targeting vector containing the hypoxanthine phosphoribosyltransferase (hprt) minigene involved insertion of fragments derived from Brca1 genomic clones on either side of the minigene in the plasmid HL2. NheI linkers were added to a 1.2 kb fragment extending from the KpnI site in exon 11 to the EcoRI site located just downstream of exon 11, and the fragment was cloned into the NheI site of HL2 downstream of the hprt minigene. A second fragment consisting of 6.8 kb of DNA extending upstream from the XhoI site just 5' to exon 11 was inserted just 5' to the hprt minigene in HL2. The targeting vector was linearized with PvuI prior to electroporation.
ES cell culture
ES cells were cultured as described (Mohn and Koller, 1995) on embryonic feeder layers. All lines were passed at approximately 2610 6 every 3 ± 5 days. Electroporation was carried out in the presence of 3 mM of the indicated linearized plasmid. To isolate a Brca1 7/7 cell line, the Brca1 +/7 cell line 203 ± 33 was electroporated with the targeting plasmid containing the hprt minigene (Reid et al., 1990) , and transfected cells were selected in HAT containing medium (16 mg/ml hypoxanthine, 0.175 mg/ml aminopterin, and 4.7 mg/ml thymidine). After electroporation, cells were diluted and counted. In experiments designed to establish the frequency of homologous and non-homologous recombination, the percentage of cells surviving electroporation was determined by plating between 1000 and 20 000 cells on a 100 mm tissue culture plate in regular medium. The remaining cells were plated at 5610 6 /100 mm plate and subjected to selection in HAT media 24 or 48 h after electroporation. Ten to 14 days later the media was removed and the cells stained with Coomassie blue. The number of colonies that grew in the absence of selection was counted to establish the percentage of cells that had survived the electroporation. The number of colonies that grew in the presence of HAT containing medium was counted and corrected using the per cent survival to determine transformation and targeting frequencies based on starting cell numbers.
Construction of the Brca1 transgene
The portion of the expression vector used for correction of BRCA1 de®ciency was constructed by assembling 5' and 3' cDNA fragments obtained by RT PCR with the central portion of exon 11 obtained from a Brca1 genomic clone. The 5' end of the coding sequence was ampli®ed from total RNA obtained from the E14TG2a ES cell line using primers that bound to sequences in exon 1 (5'-TCTCTTGGGGCTTCTCCGTCCTC-3') and to the 5' end of exon 11 (5'-ACCCCCATCCACTTCGTT-3'), respectively. The 3' end of the Brca1 coding sequence was ampli®ed in a similar manner using primers that bound to the 3' end of exon 11 (5'-GATCTTCCCTGCTTCAACACTTA-3') and to exon 24 (5'-CAGGCGGATGCATGAAAAATACTT-3'), respectively. The 5' and 3' RT PCR products were cloned into the PCRII cloning vector (Invitrogen) according to the protocol provided by the supplier to produce pBC5' and pBC3', respectively. The central portion of exon 11 was excised from pBrcag, a genomic clone containing Brca1 sequences including exons 11 and 12, using EcoRI and HinDIII. This fragment was subcloned into pBluescript II SK+ (Stratagene) to produce pBCM. The 3' end of the coding sequence was excised from pBC3' with HinDIII and ligated into the HinDIII site of pBCM at the 3' end of the exon 11 fragment to produce pBCM3'. The 5' end of the coding sequence was isolated as a SpeI, HpaI fragment from pBC5' and ligated between the XbaI and HpaI sites at the 5' end of exon 11 in pBCM3'. A XhoI fragment encompassing exons 11 and 12 of the Brca1 gene was isolated from a genomic clone and ligated into the XhoI site of pBlueScript to produce p3'Xho. An XbaI, XhoI fragment containing the bovine growth hormone polyadenlyation signal from pIREShygro was inserted into p3'Xho at the 5' end of the Brca1 sequences to produce ppAXho. The entire insert containing the polyadenylation signal and the Brca1 genomic sequences was excised from ppAXho with ApaI and SpeI and inserted between the ApaI and XbaI sites of pBCM3' downstream of the Brca1 coding sequence. The genomic fragment from p3'Xho was included at the 3' end of the Brca1 transgene with the original intent of using the plasmid as a targeting vector for displacing the hprt minigene from the targeted locus by homologous recombination. The promoter region of the Brca1 transgene was derived from pBrcaf, a Brca1 genomic clone carrying the initial exons of both the Brca1 gene and the Nbr1 gene, which lies immediately upstream of the Brca1 gene and is transcribed in the opposite direction. The promoter was isolated as a 4 kb BamHI fragment encompassing sequences immediately upstream of the Brca1 start site. The promoter region was initially cloned into the BamHI site of pSL1180 (Pharmacia) to produce pBPBam. The promoter fragment was excised from pBPBam with SacII and Bsp120 I and inserted between the SacII and NotI sites of pBrpAX at the 5' end of the Brca1 coding sequence to produce the ®nal expression vector, pBBrpAX.
RNA preparation and northern analysis
Total RNA was prepared from ES cell lines using RNAzol B (Tel-test) following the manufacturer's instructions. Twenty mg of RNA was fractionated by electrophoresis on a 1% agarose/formaldehyde gel, transferred to nitrocellulose membranes, and hybridized with a radioactive probe corresponding to Brca1 exons 2 ± 10. RtPCR of the Brca1 derived mRNA present in the Brca1 7/7 line was carried out using forward (5'-AAACAGGCAGACCCAACC-3') and reverse (5'-AGCTGCAGCATCCTCTCC-3') primers. The resulting product was ligated into the PCRII cloning vector (Invitrogen) according to the manufacturer's instructions and subjected to sequence analysis.
